Websense Inc. (NASDAQ: WBSN), Windstream (NYSE: WIN), Applied Materials, Inc. (NASDAQ: AMAT), Watson Pharmaceuticals Incorporated (NYSE: WPI), Abbott Laboratories (NYSE: ABT) and AEterna Zentaris Inc. (NASDAQ: AEZS) had ratings on them reiterated by analysts.
Stifel Nicolaus reiterated its "Hold" rating on Websense Inc. (WBSN).
Gabelli reiterated its "Hold" rating on Windstream (WIN).
Stifel Nicolaus reiterated its "Buy" rating on Applied Materials, Inc. (AMAT). They have a price target of $14.00 on the company.
Piper Jaffray (NYSE:PJC) reiterated its "Overweight" rating on Watson Pharmaceuticals Incorporated (WPI). They have a price target of $78.00 on the company.
Morgan Stanley (NYSE:MS) reiterated its "Overweight" rating on Abbott Laboratories (ABT).
Rodman & Renshaw reiterated its "Outperform" rating on AEterna Zentaris Inc. (AEZS). They have a price target of $3.00 on the company.
Showing posts with label Abbot Laboratories. Show all posts
Showing posts with label Abbot Laboratories. Show all posts
Tuesday, November 15, 2011
Thursday, August 25, 2011
Randgold (GOLD) (ABT) (UTHR) (BHE) (SANM) (BSX) Downgraded
Randgold Resources Ltd. (NASDAQ: GOLD), Abbott Laboratories (NYSE: ABT), United Therapeutics (NASDAQ: UTHR), Benchmark Electronics, Inc. (NYSE: BHE), Sanmina-SCI Co. (NASDAQ: SANM) and Boston Scientific (NYSE: BSX) downgraded by analysts.
Randgold Resources Ltd. (GOLD) was downgraded by RBC Capital from an “Outperform” rating to a “Sector Perform” rating.
Abbott Laboratories (ABT) was downgraded by Morgan Keegan from an “Outperform” rating to a “Market Perform” rating. They have a price target of $57.00 on the company, down from $60.00.
United Therapeutics (UTHR) was downgraded by JPMorgan Chase & Co. (NYSE:JPM) from an “Overweight” rating to a “Neutral” rating.
Benchmark Electronics, Inc. (BHE) was downgraded by RBC Capital from an “Outperform” rating to a “Sector Perform” rating. They have a price target of $13.00 on the company, down from $20.00.
Sanmina-SCI Co. (SANM) was downgraded by RBC Capital from a “Sector Perform” rating to an “Underperform” rating. They have a price target $5.00 on the company, down from $12.00.
Boston Scientific (BSX) was downgraded by Morgan Keegan from an “Outperform” rating to a “Market Perform” rating. They have a price target of $7.00 on the company, down from $8.00.
Randgold Resources Ltd. (GOLD) was downgraded by RBC Capital from an “Outperform” rating to a “Sector Perform” rating.
Abbott Laboratories (ABT) was downgraded by Morgan Keegan from an “Outperform” rating to a “Market Perform” rating. They have a price target of $57.00 on the company, down from $60.00.
United Therapeutics (UTHR) was downgraded by JPMorgan Chase & Co. (NYSE:JPM) from an “Overweight” rating to a “Neutral” rating.
Benchmark Electronics, Inc. (BHE) was downgraded by RBC Capital from an “Outperform” rating to a “Sector Perform” rating. They have a price target of $13.00 on the company, down from $20.00.
Sanmina-SCI Co. (SANM) was downgraded by RBC Capital from a “Sector Perform” rating to an “Underperform” rating. They have a price target $5.00 on the company, down from $12.00.
Boston Scientific (BSX) was downgraded by Morgan Keegan from an “Outperform” rating to a “Market Perform” rating. They have a price target of $7.00 on the company, down from $8.00.
Wednesday, July 13, 2011
Chevron (CVX) (AAPL) (AMAT) (ABT) (TK) EPS Estimates Changed
Chevron (NYSE: CVX), Apple, Inc (NASDAQ: AAPL), Applied Materials, Inc. (NASDAQ: AMAT), Abbott Laboratories (NYSE: ABT) and Teekay Co. (NYSE: TK) EPS estimates adjusted by analysts.
UBS AG (NYSE:UBS) boosted its EPS estimate on Chevron (CVX). They have a "Buy" rating on the energy giant and a price target of $127.00 on the company.
JPMorgan Chase & Co. (NYSE:JPM) cut their EPS estimate on shares of Applied Materials (AMAT). They have a "Neutral" rating on Applied and a price target of $12.00 on the company.
Credit Suisse (NYSE:CS) slashed their EPS estimate on Apple (AAPL). They have an "Outperform" rating on Apple with a price target of $500.00 on the company.
Jefferies (NYSE:JEF) lowered their EPS estimate on Teekay Co. (TK). They have a "Buy" rating on Teekay and a price target of $41.00 on the company.
UBS AG (NYSE:UBS) raised their EPS estimate on Abbott Laboratories (ABT). They have a "Buy" rating on the company and a price target of $59.00 on the company.
Abbott Laboratories closed Tuesday at $53.29, gaining $0.11, or 0.21 percent. Chevron ended the session at $104.39, down $0.02, or 0.02 percent. Applied Materials closed at $12.64, falling $0.34, or 2.62 percent. Apple closed at $353.75, losing $0.25, or 0.07 percent. Teekay closed at $30.27, up $0.04, or 0.13 percent.
UBS AG (NYSE:UBS) boosted its EPS estimate on Chevron (CVX). They have a "Buy" rating on the energy giant and a price target of $127.00 on the company.
JPMorgan Chase & Co. (NYSE:JPM) cut their EPS estimate on shares of Applied Materials (AMAT). They have a "Neutral" rating on Applied and a price target of $12.00 on the company.
Credit Suisse (NYSE:CS) slashed their EPS estimate on Apple (AAPL). They have an "Outperform" rating on Apple with a price target of $500.00 on the company.
Jefferies (NYSE:JEF) lowered their EPS estimate on Teekay Co. (TK). They have a "Buy" rating on Teekay and a price target of $41.00 on the company.
UBS AG (NYSE:UBS) raised their EPS estimate on Abbott Laboratories (ABT). They have a "Buy" rating on the company and a price target of $59.00 on the company.
Abbott Laboratories closed Tuesday at $53.29, gaining $0.11, or 0.21 percent. Chevron ended the session at $104.39, down $0.02, or 0.02 percent. Applied Materials closed at $12.64, falling $0.34, or 2.62 percent. Apple closed at $353.75, losing $0.25, or 0.07 percent. Teekay closed at $30.27, up $0.04, or 0.13 percent.
Wednesday, May 4, 2011
Pharmaceuticals (LLY) (BMY) (ABT) (PFE) (TEVA) Trade Mixed Tuesday
Shares of pharmaceuticals Eli Lilly (NYSE:LLY), Bristol-Myers Squibb (NYSE:BMY), Abbott Labs (NYSE:ABT), Pfizer (NYSE:PFE) and Teva (NASDAQ:TEVA) closed mixed Tuesday, with the NYSE Drug index ending the session at 331.74.
Leading the drug winners on Tuesday was Eli Lilly (:LLY), which closed at $38.09, gaining $0.78, or 2.09 percent.
Bristol-Myers Squibb (BMY) also had a good Tuesday, closing the session at $28.83, up $0.38, or 1.34 percent.
Next was Abbott Labs (ABT), which closed out at $52.85, rising $0.26, or 0.49 percent.
Pfizer (PFE) was on the other end of the action, plunging $0.58, or 2.76, to end the day at $20.44. Teva was also under pressure, closing at $46.46, down $0.81, or 1.71 percent.
Leading the drug winners on Tuesday was Eli Lilly (:LLY), which closed at $38.09, gaining $0.78, or 2.09 percent.
Bristol-Myers Squibb (BMY) also had a good Tuesday, closing the session at $28.83, up $0.38, or 1.34 percent.
Next was Abbott Labs (ABT), which closed out at $52.85, rising $0.26, or 0.49 percent.
Pfizer (PFE) was on the other end of the action, plunging $0.58, or 2.76, to end the day at $20.44. Teva was also under pressure, closing at $46.46, down $0.81, or 1.71 percent.
Monday, May 2, 2011
Dividend Yields for (LLY) (BMY) (MRK) (PFE) (ABT)
Indicated dividend yields for Standard & Poor's 500 Index companies Eli Lilly & Co (LLY), Bristol-Myers Squibb Co (BMY), Merck & Co Inc (MRK), Pfizer Inc (PFE) and Abbott Laboratories (ABT).
These dividend data indicate dividend yields of companies in the Standard & Poor's 500 Index as of Saturday, April 30. The yield is determined by taking the latest declared dividend, annualized and divided by the price of the stock. Payout ratios are calculated based on latest quarterly dividend paid divided by earnings.
Eli Lilly & Co (LLY) has a dividend yield of 5.29 percent on a declared dividend of $0.49. The payout ratio is 51.6 percent.
Bristol-Myers Squibb Co (BMY) has a dividend yield of 4.70 percent on a declared dividend of $0.33. The payout ratio is 57.0 percent.
Merck & Co Inc (MRK) has a dividend yield of 4.23 percent on a declared dividend of $0.38. The payout ratio is 113.1 percent.
Pfizer Inc (PFE) has a dividend yield of 3.81 percent on a declared dividend of $0.20. The payout ratio is 49.8 percent.
Abbott Laboratories (ABT) has a dividend yield of 3.69 percent on a declared dividend of $0.48. The payout ratio is 79.4 percent.
These dividend data indicate dividend yields of companies in the Standard & Poor's 500 Index as of Saturday, April 30. The yield is determined by taking the latest declared dividend, annualized and divided by the price of the stock. Payout ratios are calculated based on latest quarterly dividend paid divided by earnings.
Eli Lilly & Co (LLY) has a dividend yield of 5.29 percent on a declared dividend of $0.49. The payout ratio is 51.6 percent.
Bristol-Myers Squibb Co (BMY) has a dividend yield of 4.70 percent on a declared dividend of $0.33. The payout ratio is 57.0 percent.
Merck & Co Inc (MRK) has a dividend yield of 4.23 percent on a declared dividend of $0.38. The payout ratio is 113.1 percent.
Pfizer Inc (PFE) has a dividend yield of 3.81 percent on a declared dividend of $0.20. The payout ratio is 49.8 percent.
Abbott Laboratories (ABT) has a dividend yield of 3.69 percent on a declared dividend of $0.48. The payout ratio is 79.4 percent.
Monday, April 4, 2011
Boston Scientific (BSX) Stent Confirmed Effective
In a clinical trial a heart stent manufactured by Boston Scientific Corp. (NYSE:BSX) has been proven to be as effective as one already on the market, which was developed by Abbott Laboratories Inc (NYSE:ABT), a major competitor of BSX.
when compared with the older Promus, which is sold by Abbott under the brand name Xience, study of 1,750 patients from around the globe found the new drug-eluting Promus Element stent was comparable in results.
Conclusions were there were no measurable differences between Promus Element and Xience in regard to effectiveness and safety.
Boston Scientific was trading at $7.12, falling $0.18, or 2.47 percent, as of 12:41 PM EDT. Abbott Laboratories Inc was trading at $50.31, gaining $0.94, or 1.90 percent.
when compared with the older Promus, which is sold by Abbott under the brand name Xience, study of 1,750 patients from around the globe found the new drug-eluting Promus Element stent was comparable in results.
Conclusions were there were no measurable differences between Promus Element and Xience in regard to effectiveness and safety.
Boston Scientific was trading at $7.12, falling $0.18, or 2.47 percent, as of 12:41 PM EDT. Abbott Laboratories Inc was trading at $50.31, gaining $0.94, or 1.90 percent.
Wednesday, March 30, 2011
Bristol-Myers' (BMY) Orencia Fails to Get U.K. Approval
Saying the arthritis drug Orencia isn't a cost-effective alternative to other drugs, the U.K.’s health-cost agency said they don't back the offering by Bristol-Myers Squibb Co. (NYSE:BMY).
Bristol-Myers Squibb Co. failed to win the backing of the U.K.’s health-cost agency for treating moderate to severe rheumatoid arthritis in patients who haven’t responded to one or more disease-modifying drugs.
Orencia, in combination with older medicine methotrexate, isn’t a cost-effective use of National Health Service funds compared with rival treatments, the National Institute for Health and Clinical Excellence said today in an e-mailed statement. The agency already recommends four medicines for second-line use: Abbott Laboratories (NYSE:ABT)’ Humira, Pfizer Inc. (NYSE:PFE)’s Enbrel, Merck & Co.’s (NYSE:MRK) Remicade and UCB SA (UCB)’s Cimzia.
Bristol-Myers closed Tuesday at $26.84, down $0.14, or 0.52 percent.
Source
Bristol-Myers Squibb Co. failed to win the backing of the U.K.’s health-cost agency for treating moderate to severe rheumatoid arthritis in patients who haven’t responded to one or more disease-modifying drugs.
Orencia, in combination with older medicine methotrexate, isn’t a cost-effective use of National Health Service funds compared with rival treatments, the National Institute for Health and Clinical Excellence said today in an e-mailed statement. The agency already recommends four medicines for second-line use: Abbott Laboratories (NYSE:ABT)’ Humira, Pfizer Inc. (NYSE:PFE)’s Enbrel, Merck & Co.’s (NYSE:MRK) Remicade and UCB SA (UCB)’s Cimzia.
Bristol-Myers closed Tuesday at $26.84, down $0.14, or 0.52 percent.
Source
Tuesday, February 1, 2011
DepoMed (Nasdaq:DEPO) Shares Explode on Gralise Approval
Shares of DepoMed (Nasdaq:DEPO) soared Monday on news the U.S. Food and Drug Administration (FDA) approved its Gralise treatment, which will be used for painful complications related to shingles.
That wasn't the only good news though, as that also triggered a $48 million payment Abbott Laboratories (NYSE:ABT) for reaching the milestone.
Shares of DepoMed exploded to $8.38, gaining $2.14, or 34.29 percent. Trading volume was over 10 times the 3-month average.
That wasn't the only good news though, as that also triggered a $48 million payment Abbott Laboratories (NYSE:ABT) for reaching the milestone.
Shares of DepoMed exploded to $8.38, gaining $2.14, or 34.29 percent. Trading volume was over 10 times the 3-month average.
Tuesday, January 25, 2011
Pfizer (NYSE:PFE), Eli Lilly (NYSE:LLY), Abbot (NYSE:ABT),Bristol-Myers (NYSE:BMY), Merck (NYSE:MRK), Face EPS Pressure on Expirations
Major pharmaceuticals like Pfizer (NYSE:PFE), Eli Lilly (NYSE:LLY), Abbot (NYSE:ABT),Bristol-Myers (NYSE:BMY) and Merck (NYSE:MRK) will be EPS pressure over the next several years, as patents on major drugs expire at each of the companies.
Barclays says, "The U.S. Major Pharma industry careens to the edge of the Patent Cliff as the year 2011 unfolds. Throughout the next 24-36 months, we expect to see U.S. patent expiries on Lipitor (PFE), Zyprexa (LLY), TriCor (ABT), Plavix (BMY), Singulair (MRK), and Cymbalta (LLY). Further, we estimate the group will face an average of 5-10% in EPS downside pressure from additional U.S. Healthcare Reform measures and European pricing pressures in 2011. We expect limited upside to top-line and earnings guidance for the year. We believe this year will be critical for providing investors with a view beyond the cliff: will the industry be able to inflect its multiple trajectories after the 2011-2013 trough years?
"Rating based on long-term revenue and EPS growth: ABT (OW)(PT $55) and MRK (OW)(PT $41) have the highest estimated growth rate in 2011-2016 (revenue CAGRs of 4% and 1%, EPS CAGRs of 8% and 6%, respectively). Our projections are inclusive of recent pipeline setbacks (i.e. termination of ABT's Certriad and delay of ABT-874, reduced estimates for MRK's Vorapaxar and impact of the Johnson&Johnson (NYSE:JNJ) arbitration over Remicade). We are reducing our price target for ABT by 8% to $55 (from $60) and MRK by 5% to $41 (from $43), largely to reflect the sentimental negatives arising from the above-referenced setbacks, despite the continuity of our long-term views. We estimate PFE (OW)(PT $21) and BMY (OW)(PT $28) face -1% and -2% revenue declines during the 2011-2016 window and largely flat EPS trajectory. LLY (EW)(PT $39) looks least attractive, with our estimate of -3% revenue CAGR during the 2011-2016 window."
Merck closed Monday at $33.80, down $0.10, or 0.29 percent. Bristol-Myers closed at $26.00, dropping $0.06, or 0.23 percent. Abbot closed at $48.17, up $0.25, or 0.52 percent. Eli Lilly closed up at $34.78, gaining $0.02, or 0.06 percent. Pfizer ended the session at $18.45, up $0.09, or 0.50 percent.
Barclays says, "The U.S. Major Pharma industry careens to the edge of the Patent Cliff as the year 2011 unfolds. Throughout the next 24-36 months, we expect to see U.S. patent expiries on Lipitor (PFE), Zyprexa (LLY), TriCor (ABT), Plavix (BMY), Singulair (MRK), and Cymbalta (LLY). Further, we estimate the group will face an average of 5-10% in EPS downside pressure from additional U.S. Healthcare Reform measures and European pricing pressures in 2011. We expect limited upside to top-line and earnings guidance for the year. We believe this year will be critical for providing investors with a view beyond the cliff: will the industry be able to inflect its multiple trajectories after the 2011-2013 trough years?
"Rating based on long-term revenue and EPS growth: ABT (OW)(PT $55) and MRK (OW)(PT $41) have the highest estimated growth rate in 2011-2016 (revenue CAGRs of 4% and 1%, EPS CAGRs of 8% and 6%, respectively). Our projections are inclusive of recent pipeline setbacks (i.e. termination of ABT's Certriad and delay of ABT-874, reduced estimates for MRK's Vorapaxar and impact of the Johnson&Johnson (NYSE:JNJ) arbitration over Remicade). We are reducing our price target for ABT by 8% to $55 (from $60) and MRK by 5% to $41 (from $43), largely to reflect the sentimental negatives arising from the above-referenced setbacks, despite the continuity of our long-term views. We estimate PFE (OW)(PT $21) and BMY (OW)(PT $28) face -1% and -2% revenue declines during the 2011-2016 window and largely flat EPS trajectory. LLY (EW)(PT $39) looks least attractive, with our estimate of -3% revenue CAGR during the 2011-2016 window."
Merck closed Monday at $33.80, down $0.10, or 0.29 percent. Bristol-Myers closed at $26.00, dropping $0.06, or 0.23 percent. Abbot closed at $48.17, up $0.25, or 0.52 percent. Eli Lilly closed up at $34.78, gaining $0.02, or 0.06 percent. Pfizer ended the session at $18.45, up $0.09, or 0.50 percent.
Subscribe to:
Comments (Atom)